Compare TGL & DRMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGL | DRMA |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 5.6M |
| IPO Year | 2022 | 2021 |
| Metric | TGL | DRMA |
|---|---|---|
| Price | $2.13 | $1.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | ★ 142.7K | 33.1K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,330,557.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $650.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.26 | $0.95 |
| 52 Week High | $58.00 | $5.87 |
| Indicator | TGL | DRMA |
|---|---|---|
| Relative Strength Index (RSI) | 42.38 | 42.03 |
| Support Level | $2.04 | $1.11 |
| Resistance Level | $3.30 | $1.40 |
| Average True Range (ATR) | 0.37 | 0.08 |
| MACD | -0.06 | -0.00 |
| Stochastic Oscillator | 9.27 | 35.76 |
Treasure Global Inc has created an online-to-offline e-commerce platform business model that offers consumers and merchants instant rebates and affiliate cashback programs, while providing a seamless e-payment solution with rebates in both e-commerce and physical retail or merchant settings. Its product is an internet application branded as the ZCITY app, which targets consumers by providing personalized deals based on their purchase history, location, and preferences. The Company has two reportable segments: payment processing and e-commerce operation in its ZCITY platform, and customized software development service, and the majority of revenue comes from payment processing and e-commerce operation in its ZCITY platform.
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.